EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

Launched by FUJIAN CANCER HOSPITAL · Oct 24, 2018

Keywords

ClinConnect Summary

This trial investigated the efficacy and safety of EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant NSCLC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Age ≥ 18 years
• • ECOG performance status 0-1
• • Adequate haematological function, coagulation, liver function and renal function
• • Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC)
• • TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease)
• • Measurable or evaluable disease (according to RECIST 1.1 criteria).
• • Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)
• Exclusion Criteria:
• • - Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma.
• • Patients with any known significant ophthalmologic anomaly of the ocular surface
• • Patients who received prior chemotherapy for metastatic disease
• • CNS metastases
• • Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF
• • Pregnancy